Showing 1 - 4 results of 4 for search 'Khatija Ahmed', query time: 0.02s Refine Results
  1. 1
    Innovative timing strategies for tuberculosis household contact investigation: cost-effectiveness analysis from a randomized trial in rural and urban South Africa (Kharituwe Study)Research in context

    Innovative timing strategies for tuberculosis household contact investigation: cost-effectiveness analysis from a randomized trial in rural and urban South Africa (Kharituwe Study)... by Neenah Young, Patrick Biché, Mbali Mohlamonyane, Matshidiso Morolo, Babalwa Maholwana, Khatija Ahmed, Neil Martinson, Colleen F. Hanrahan, David W. Dowdy

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trial.

    Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trial. by Robert S Wallis, Sibuse Ginindza, Trevor Beattie, Nishanee Arjun, Morongwe Likoti, Modulakgotla Sebe, Vinodh A Edward, Mohammed Rassool, Khatija Ahmed, Katherine Fielding, Bintou A Ahidjo, Mboyo D T Vangu, Gavin Churchyard

    Published 2022-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    High HIV incidence among young women in South Africa: Data from a large prospective study.

    High HIV incidence among young women in South Africa: Data from a large prospective study. by Thesla Palanee-Phillips, Helen V Rees, Kate B Heller, Khatija Ahmed, Joanne Batting, Ivana Beesham, Renee Heffron, Jessica Justman, Heeran Makkan, Timothy D Mastro, Susan A Morrison, Nelly Mugo, Gonasagrie Nair, James Kiarie, Neena M Philip, Melanie Pleaner, Krishnaveni Reddy, Pearl Selepe, Petrus S Steyn, Caitlin W Scoville, Jenni Smit, Katherine K Thomas, Deborah Donnell, Jared M Baeten, ECHO Trial Consortium

    Published 2022-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial

    Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in pe... by Vivek Shinde, Anthonet Lombard Koen, Zaheer Hoosain, Moherndran Archary, Qasim Bhorat, Lee Fairlie, Umesh Lalloo, Mduduzi S. L. Masilela, Dhayendre Moodley, Sherika Hanley, Leon Frederik Fouche, Cheryl Louw, Michele Tameris, Nishanta Singh, Ameena Goga, Keertan Dheda, Coert Grobbelaar, Natasha Joseph, Johan J. Lombaard, Rosie Mngqibisa, As’ad Ebrahim Bhorat, Gabriella Benadé, Natasha Lalloo, Anna Pitsi, Pieter-Louis Vollgraaff, Angelique Luabeya, Aliasgar Esmail, Friedrich G. Petrick, Aylin Oommen Jose, Sharne Foulkes, Khatija Ahmed, Asha Thombrayil, Dishiki Kalonji, Shane Cloney-Clark, Mingzhu Zhu, Chijioke Bennett, Gary Albert, Alex Marcheschi, Joyce S. Plested, Susan Neal, Gordon Chau, Iksung Cho, Louis Fries, Greg M. Glenn, Shabir A. Madhi

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: